Celcuity Inc.
CELC
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.7B
$95.70
▼ -0.76%
P/E
-22.31
Mkt Cap
$4.7B
52-Wk Range
$44.42–$151.02
52-Week Range
$44.42 - $151.02
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 53.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CELsignia platform using living tumor cells for personalized therapy matching
- Strategic partnership with Pfizer for Gedatolisib development and commercialization rights
- First-mover advantage in functional precision medicine diagnostics for cancer treatment selection
- Multi-indication pipeline potential with platform applicability across cancer types
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Stable outlook
Clinical advancement of Gedatolisib toward regulatory approval and commercialization
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+9.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CELC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of -$1.44 vs -$1.16 consensus (-24.1% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-24.1%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$94.0K
Margins · last 8Q
Gross
50.0%
Profit
-83897.9%
Wall Street consensus
8 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 17, 2026
vs Industry
How CELC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related